KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Retained Earnings: 2011-2025

Historic Retained Earnings for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $522.0 million.

  • Supernus Pharmaceuticals' Retained Earnings fell 3.53% to $522.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $522.0 million, marking a year-over-year decrease of 3.53%. This contributed to the annual value of $556.4 million for FY2024, which is 15.31% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Retained Earnings of $522.0 million as of Q3 2025, which was down 7.96% from $567.1 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Retained Earnings peaked at $567.1 million during Q2 2025, and registered a low of $332.2 million during Q1 2021.
  • Moreover, its 3-year median value for Retained Earnings was $502.6 million (2024), whereas its average is $516.0 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first surged by 50.27% in 2021, then dropped by 3.53% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Retained Earnings (Quarterly) stood at $379.9 million in 2021, then rose by 26.67% to $481.2 million in 2022, then increased by 0.27% to $482.6 million in 2023, then rose by 15.31% to $556.4 million in 2024, then dropped by 3.53% to $522.0 million in 2025.
  • Its last three reported values are $522.0 million in Q3 2025, $567.1 million for Q2 2025, and $544.6 million during Q1 2025.